Volatility and Risk
Clever Leaves has a beta of 3784.43, suggesting that its stock price is 378,343% more volatile than the S&P 500. Comparatively, AB Corporate Bond ETF has a beta of 0.17, suggesting that its stock price is 83% less volatile than the S&P 500.
Earnings & Valuation
This table compares Clever Leaves and AB Corporate Bond ETF”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Clever Leaves | $17.42 million | 0.00 | -$17.90 million | ($12.36) | N/A |
| AB Corporate Bond ETF | $12,059.00 | 2,339.17 | -$8.09 million | ($1.68) | -20.99 |
Profitability
This table compares Clever Leaves and AB Corporate Bond ETF’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Clever Leaves | N/A | N/A | N/A |
| AB Corporate Bond ETF | N/A | -104.96% | -60.03% |
Insider & Institutional Ownership
6.9% of Clever Leaves shares are owned by institutional investors. Comparatively, 64.2% of AB Corporate Bond ETF shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by insiders. Comparatively, 58.2% of AB Corporate Bond ETF shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Clever Leaves beats AB Corporate Bond ETF on 5 of the 9 factors compared between the two stocks.
About Clever Leaves
Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.
About AB Corporate Bond ETF
EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.
Receive News & Ratings for Clever Leaves Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clever Leaves and related companies with MarketBeat.com's FREE daily email newsletter.
